Lurasidone's US approval a milestone event for DSP
This article was originally published in Scrip
Executive Summary
In a key development for the company, Dainippon Sumitomo Pharma's (DSP) atypical antipsychotic lurasidone has been approved in the US, as Latuda, for the first-line treatment of adult schizophrenia.